VIDEO: Dapagliflozin can be administered with sparsentan in healthy adults
Click Here to Manage Email Alerts
ORLANDO — In this video from ASN Kidney Week, Jula Inrig, MD, chief medical officer of Travere Therapeutics Inc., discusses the use of dapagliflozin with sparsentan as treatment for IgA nephropathy and focal segmental glomerulosclerosis.
In an open label drug-drug interaction study, researchers explored the impact of multiple doses of sparsentan on the pharmacokinetics of single-dose dapagliflozin in 20 healthy adults.
The study was divided into two periods. Period 1 extended from day 1 to 5, during which patients received a single 10 mg dose of dapagliflozin on day 1, in addition to pharmacokinetics sampling pre-dose and up to 96 hours post-dose. Period 2 lasted from days 5 to 14, during which patients received 800 mg sparsentan once daily for 10 days with a single 10 mg dose dapagliflozin co-administered on day 11, dapagliflozin pharmacokinetics sampling pre-dose and up to 96 hours after day 11 dosing.
An ANOVA mixed model analysis of dapagliflozin revealed the maximum serum concentration and area under the curve was similar when dosed alone and when dosed with sparsentan.
“We saw essentially no significant drug-drug interactions. I think that’s really important for practicing clinicians to feel that they can have comfort if and when sparsentan gets approved,” Inrig told Healio. “The take home message is that we can see, relatively, that we can administer the two together.”
Collapse
Chen C, et al. FR-PO217. Presented at: ASN Kidney Week; Nov. 3-6, 2022; Orlando (hybrid meeting).
Click Here to Manage Email Alerts